Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Shares Bought by Exome Asset Management LLC

Exome Asset Management LLC grew its stake in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 87.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 298,575 shares of the company’s stock after purchasing an additional 139,400 shares during the period. Exome Asset Management LLC owned approximately 1.11% of Syros Pharmaceuticals worth $642,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Syros Pharmaceuticals by 21.3% in the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after buying an additional 163,234 shares in the last quarter. Acadian Asset Management LLC raised its position in Syros Pharmaceuticals by 101.5% during the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after acquiring an additional 17,416 shares during the last quarter. Certuity LLC purchased a new stake in shares of Syros Pharmaceuticals in the second quarter valued at about $109,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Syros Pharmaceuticals in the third quarter valued at approximately $34,000. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Insider Activity at Syros Pharmaceuticals

In other news, Director Nancy A. Simonian sold 134,713 shares of the stock in a transaction on Monday, November 25th. The shares were sold at an average price of $0.27, for a total value of $36,372.51. Following the completion of the sale, the director now owns 41,070 shares of the company’s stock, valued at $11,088.90. This represents a 76.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.26% of the stock is currently owned by insiders.

Syros Pharmaceuticals Stock Performance

NASDAQ:SYRS opened at $0.21 on Friday. Syros Pharmaceuticals, Inc. has a fifty-two week low of $0.18 and a fifty-two week high of $8.17. The firm’s 50 day moving average is $1.38 and its two-hundred day moving average is $3.09. The company has a market cap of $5.56 million, a P/E ratio of -0.07 and a beta of 1.33. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same period last year, the firm posted ($1.35) earnings per share. Analysts expect that Syros Pharmaceuticals, Inc. will post -2.94 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 target price (down previously from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. StockNews.com assumed coverage on Syros Pharmaceuticals in a research note on Saturday, December 7th. They set a “sell” rating on the stock. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.